A Phase 3 interventional study of ALKS 2680 Dose 1 and ALKS 2680 Dose 2 in Narcolepsy Type 2, sponsored by Alkermes, Inc.. Recruiting at 44 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Sleep Wake Disorders with a site in United States — 34 open to participants now, 40 under way, 8 of them phase 3. Sleep Wake Disorders · United States.
Among the 248 studies in Sleep Wake Disorders with a site in United States, this one is the 54th largest by planned enrollment of the 203 interventional ones that give a count, is one of 15 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 12 of the 39 other live ones, and was the 241st registered.
747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.
Browse Sleep Wake Disorders studies →34 of the 248 studies in Sleep Wake Disorders with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
Alkermes, Inc. · Sites in United States, Belgium, Canada and 2 more countries
Ages 18–70
Centessa Pharmaceuticals (UK) Limited · Sites in United States
Ages 18–70
VA Office of Research and Development · Sites in United States
Ages 60+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 110 Sleep Wake Disorders studies recruiting now, 36 (33%) set no upper age limit and 54 (49%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 27 · Phase 3 30 · Phase 4 19
First in 1996; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 176 is above the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.
Median enrollment 70 across the 203 interventional studies, 110 across the 44 observational. Of the 189 that completed or were terminated, 67 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 248 have an industry lead sponsor. The 10 most frequent:
Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
Alkermes, Inc. has 7 studies filed under Sleep Wake Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Sleep Wake Disorders with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07540897Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | 2027-06 |
| NCT07598708Phase 3Centessa Pharmaceuticals (UK) LimitedA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | 2027-09-30 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
Add all 15 to your calendar (.ics) → With an account.
Among the 248 studies in Sleep Wake Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ALKS 2680 Dose 1
Drug: ALKS 2680 Dose 2
Drug: ALKS 2680 Dose 3
Drug: Placebo
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
Also known as: Alixorexton
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
Also known as: Alixorexton
Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks
Also known as: Alixorexton
Participants will receive placebo tablets, daily, orally for 12 weeks
Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level
Time frame: Baseline to Week 12
Change in Epworth Sleepiness Scale (ESS) from baseline to Week 12 by dose level
Time frame: Baseline to Week 12
Percentage of participants who achieve a status of "none" or "mild" on Patient Global Impression-Severity (PGI-S) scale (general disease) at Week 12 by dose level
Time frame: Week 12
Change in British Columbia Cognitive Complaints Inventory (BC-CCI) from baseline to Week 12 by dose level
Time frame: Baseline to Week 12
Change in number of lapses on Psychomotor Vigilance Task (PVT) from baseline to Week 12 by dose level
Time frame: Baseline to Week 12
Change in Patient-Reported Outcomes Measurement Information System - Fatigue 6a (PROMIS Fatigue 6a) from baseline to Week 12 by dose level
Time frame: Baseline to Week 12
Percentage of participants who achieve a status of "normal, not ill at all", "borderline ill", or "mildly ill" on Clinical Global Impression-Severity (CGI-S) (general disease) at Week 12 by dose level
Time frame: Week 12
Incidence of treatment emergent adverse events
Time frame: Up to 14 weeks
Plan to share: Undecided
Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.
Of 19 phase 3 interventional studies under Sleep Wake Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 13 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.